Naldemedine + Placebo
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Opioid-Induced Constipation (OIC)
Conditions
Opioid-Induced Constipation (OIC)
Trial Timeline
Jun 6, 2025 → Sep 30, 2027
NCT ID
NCT07038551About Naldemedine + Placebo
Naldemedine + Placebo is a approved stage product being developed by Shionogi for Opioid-Induced Constipation (OIC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07038551. Target conditions include Opioid-Induced Constipation (OIC).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07038551 | Approved | Recruiting |
| NCT04355169 | Phase 2 | Terminated |
| NCT01993940 | Phase 3 | Completed |
| NCT01965652 | Phase 3 | Completed |
| NCT01965158 | Phase 3 | Completed |
| NCT01122030 | Phase 2 | Completed |
Competing Products
20 competing products in Opioid-Induced Constipation (OIC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naldemedine | Shionogi | Phase 1/2 | 41 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Placebo + Naldemedine | Shionogi | Phase 2 | 52 |
| Naldemedine + Placebo | Shionogi | Phase 3 | 77 |
| Naloxegol | Kyowa Kirin | Pre-clinical | 23 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + Usual care | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| Naloxegol + Placebo Oral Capsule | AstraZeneca | Phase 2 | 52 |
| NKTR-118 + NKTR-118 + Placebo | AstraZeneca | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| CB-5945 + Placebo | Merck | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Tegaserod | Novartis | Phase 3 | 77 |
| Methylnaltrexone bromide + Placebo | Pfizer | Phase 2 | 51 |
| ALKS 37 + Placebo | Alkermes | Phase 2 | 49 |